NASDAQ:MGEN - Miragen Therapeutics Stock Price, Price Target & More

$6.62 +0.20 (+3.12 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$6.42
Today's Range$6.35 - $6.73
52-Week Range$5.01 - $15.91
Volume81,674 shs
Average Volume272,197 shs
Market Capitalization$202.29 million
P/E Ratio-4.77
Dividend YieldN/A
Beta1.33

About Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics logoSignal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGEN
CUSIPN/A
Phone303-531-5952

Debt

Debt-to-Equity Ratio0.26%
Current Ratio13.33%
Quick Ratio13.33%

Price-To-Earnings

Trailing P/E Ratio-4.77
Forward P/E Ratio-5.96
P/E GrowthN/A

Sales & Book Value

Annual Sales$4 million
Price / Sales49.96
Cash FlowN/A
Price / CashN/A
Book Value$1.73 per share
Price / Book3.83

Profitability

EPS (Most Recent Fiscal Year)($1.38)
Net Income$-26,510,000.00
Net Margins-662.30%
Return on Equity-63.57%
Return on Assets-51.14%

Miscellaneous

Employees65
Outstanding Shares30,190,000

How to Become a New Pot Stock Millionaire

Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics Inc. (NASDAQ:MGEN) issued its earnings results on Wednesday, March, 14th. The medical research company reported ($0.29) EPS for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.04. The medical research company earned $1.19 million during the quarter, compared to analysts' expectations of $1.22 million. Miragen Therapeutics had a negative net margin of 662.30% and a negative return on equity of 63.57%. View Miragen Therapeutics' Earnings History.

What price target have analysts set for MGEN?

9 equities research analysts have issued 1-year price objectives for Miragen Therapeutics' shares. Their forecasts range from $13.00 to $29.00. On average, they expect Miragen Therapeutics' share price to reach $17.1875 in the next year. View Analyst Ratings for Miragen Therapeutics.

What are Wall Street analysts saying about Miragen Therapeutics stock?

Here are some recent quotes from research analysts about Miragen Therapeutics stock:
  • 1. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (4/21/2018)
  • 2. Cann analysts commented, "MiRagen Therapeutics announced today positive new interim data from its phase I clinical trial of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) will be presented on February 2, 2018, at the 10th Annual T-cell Lymphoma Forum in La Jolla, California. These positive results support MiRagen’s plans to initiate a phase II study of MRG-106 in CTCL in the second half of 2018. The data released today, along with the planned phase II trial design support our expectation that MRG-106 will be able to proceed to a registration phase II study, avoiding phase III trials." (2/2/2018)

Who are some of Miragen Therapeutics' key competitors?

Has Miragen Therapeutics been receiving favorable news coverage?

News stories about MGEN stock have been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Miragen Therapeutics earned a media sentiment score of 0.14 on Accern's scale. They also gave news headlines about the medical research company an impact score of 45.49 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Miragen Therapeutics?

Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $6.62.

How big of a company is Miragen Therapeutics?

Miragen Therapeutics has a market capitalization of $202.29 million and generates $4 million in revenue each year. The medical research company earns $-26,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Miragen Therapeutics employs 65 workers across the globe.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 303-531-5952 or via email at [email protected]


MarketBeat Community Rating for Miragen Therapeutics (MGEN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  218
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Miragen Therapeutics (NASDAQ:MGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Miragen Therapeutics in the last 12 months. Their average twelve-month price target is $17.1875, suggesting that the stock has a possible upside of 159.63%. The high price target for MGEN is $29.00 and the low price target for MGEN is $13.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.893.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.1875$17.6429$17.90$23.00
Price Target Upside: 159.63% upside134.92% upside122.64% upside144.16% upside

Miragen Therapeutics (NASDAQ:MGEN) Consensus Price Target History

Price Target History for Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics (NASDAQ:MGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2018CowenReiterated RatingHoldMediumView Rating Details
3/29/2018Jefferies GroupInitiated CoverageBuy -> Buy$14.00MediumView Rating Details
3/28/2018WedbushReiterated RatingOutperform$19.00MediumView Rating Details
3/22/2018Deutsche BankInitiated CoverageBuy$15.00MediumView Rating Details
3/9/2018Evercore ISIInitiated CoverageOutperform -> Outperform$19.00LowView Rating Details
2/2/2018CannReiterated RatingBuy$13.00LowView Rating Details
1/16/2018Chardan CapitalReiterated RatingBuyLowView Rating Details
1/12/2018OppenheimerInitiated CoverageOutperform$13.00HighView Rating Details
1/5/2018B. RileyInitiated CoverageBuy -> Buy$15.50HighView Rating Details
8/21/2016Rodman & RenshawSet Price TargetBuy$4.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Miragen Therapeutics (NASDAQ:MGEN) Earnings History and Estimates Chart

Earnings by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics (NASDAQ:MGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.02)
2019 EPS Consensus Estimate: ($1.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.27)($0.22)($0.25)
Q2 20182($0.27)($0.23)($0.25)
Q3 20182($0.27)($0.24)($0.26)
Q4 20182($0.27)($0.26)($0.27)
Q1 20191($0.29)($0.29)($0.29)
Q2 20191($0.28)($0.28)($0.28)
Q3 20191($0.27)($0.27)($0.27)
Q4 20191($0.26)($0.26)($0.26)

Miragen Therapeutics (NASDAQ MGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018Q4 2017($0.33)($0.29)$1.22 million$1.19 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.3930)($0.27)$0.72 million$1.63 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.47)($0.34)$0.46 million$0.72 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.24)($0.60)$1.00 million$0.46 millionViewN/AView Earnings Details
3/24/2017Q4 2016($7.72)$0.76 millionViewN/AView Earnings Details
8/15/2016Q2 2016($4.05)($3.45)$1.00 million$0.87 millionViewN/AView Earnings Details
5/16/2016Q116($0.28)($0.26)$645.00 million$808.00 millionViewN/AView Earnings Details
3/16/2016Q415($0.36)($0.28)$0.60 million$0.66 millionViewN/AView Earnings Details
11/12/2015Q3 2015($5.85)$0.50 millionViewN/AView Earnings Details
8/12/2015Q215($0.39)($0.33)$0.73 millionViewN/AView Earnings Details
5/14/2015Q115($0.36)($0.45)$1.90 million$0.65 millionViewN/AView Earnings Details
3/30/2015($0.39)($1.72)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.05)($0.43)$1.30 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Miragen Therapeutics (NASDAQ:MGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Miragen Therapeutics (NASDAQ MGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.40%
Institutional Ownership Percentage: 18.98%
Insider Trading History for Miragen Therapeutics (NASDAQ:MGEN)
Institutional Ownership by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics (NASDAQ MGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Adam Scott LevyInsiderBuy9,090$5.50$49,995.0010,540View SEC Filing  
2/13/2018Bruce BoothDirectorBuy545,454$5.50$2,999,997.00View SEC Filing  
12/20/2017Thomas E. HughesDirectorSell12,000$8.00$96,000.00View SEC Filing  
6/22/2017Adam Scott LevyInsiderBuy200$7.55$1,510.00200View SEC Filing  
3/10/2017Kyle LefkoffDirectorSell5,800$14.34$83,172.00View SEC Filing  
3/8/2017Kyle LefkoffDirectorSell15,000$15.40$231,000.00View SEC Filing  
2/28/2017Kyle LefkoffDirectorSell10,258$13.89$142,483.62View SEC Filing  
2/23/2017Kyle LefkoffDirectorSell5,902$14.14$83,454.28View SEC Filing  
11/20/2015Samuel D. RiccitelliCEOBuy14,000$0.79$11,060.00345,130View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Miragen Therapeutics (NASDAQ MGEN) News Headlines

Source:
DateHeadline
$1.17 Million in Sales Expected for Miragen Therapeutics Inc. (MGEN) This Quarter$1.17 Million in Sales Expected for Miragen Therapeutics Inc. (MGEN) This Quarter
www.americanbankingnews.com - April 23 at 2:08 AM
 Brokerages Expect Miragen Therapeutics Inc. (MGEN) to Announce -$0.26 EPS Brokerages Expect Miragen Therapeutics Inc. (MGEN) to Announce -$0.26 EPS
www.americanbankingnews.com - April 21 at 9:06 PM
Miragen Therapeutics (MGEN) Rating Lowered to Hold at Zacks Investment ResearchMiragen Therapeutics (MGEN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 21 at 7:24 AM
Miragen Therapeutics (MGEN) Upgraded to "Hold" at ValuEngineMiragen Therapeutics (MGEN) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 20 at 1:19 PM
Miragen Therapeutics (MGEN) Raised to Buy at Zacks Investment ResearchMiragen Therapeutics (MGEN) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:00 AM
Miragen Therapeutics (MGEN) Stock Rating Reaffirmed by Chardan CapitalMiragen Therapeutics (MGEN) Stock Rating Reaffirmed by Chardan Capital
www.americanbankingnews.com - April 16 at 12:02 PM
Head-To-Head Analysis: Miragen Therapeutics (MGEN) vs. The CompetitionHead-To-Head Analysis: Miragen Therapeutics (MGEN) vs. The Competition
www.americanbankingnews.com - April 15 at 11:14 PM
Miragen Therapeutics Inc. (MGEN) Given Average Recommendation of "Buy" by AnalystsMiragen Therapeutics Inc. (MGEN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 15 at 9:57 AM
Head to Head Comparison: Miragen Therapeutics (MGEN) versus Its RivalsHead to Head Comparison: Miragen Therapeutics (MGEN) versus Its Rivals
www.americanbankingnews.com - April 12 at 9:51 AM
Financial Review: Miragen Therapeutics (MGEN) vs. Its CompetitorsFinancial Review: Miragen Therapeutics (MGEN) vs. Its Competitors
www.americanbankingnews.com - April 12 at 1:15 AM
Miragen Therapeutics (MGEN) Rating Reiterated by Chardan CapitalMiragen Therapeutics (MGEN) Rating Reiterated by Chardan Capital
www.americanbankingnews.com - April 10 at 5:03 PM
Miragen Therapeutics (MGEN) Stock Rating Upgraded by Zacks Investment ResearchMiragen Therapeutics (MGEN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 10 at 9:44 AM
Miragen Therapeutics (MGEN) "Hold" Rating Reiterated at CowenMiragen Therapeutics' (MGEN) "Hold" Rating Reiterated at Cowen
www.americanbankingnews.com - April 9 at 6:02 AM
Form 8-K MIRAGEN THERAPEUTICS, For: Apr 03Form 8-K MIRAGEN THERAPEUTICS, For: Apr 03
www.streetinsider.com - April 8 at 3:10 PM
Financial Survey: Miragen Therapeutics (MGEN) and Its RivalsFinancial Survey: Miragen Therapeutics (MGEN) and Its Rivals
www.americanbankingnews.com - April 7 at 1:26 PM
 Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Post Quarterly Sales of $1.17 Million Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Post Quarterly Sales of $1.17 Million
www.americanbankingnews.com - April 6 at 1:56 AM
Miragen Therapeutics (MGEN) Downgraded to Hold at Zacks Investment ResearchMiragen Therapeutics (MGEN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 11:52 PM
Miragen Therapeutics (MGEN) vs. Its Peers Head-To-Head ContrastMiragen Therapeutics (MGEN) vs. Its Peers Head-To-Head Contrast
www.americanbankingnews.com - April 5 at 3:08 AM
-$0.26 EPS Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter-$0.26 EPS Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter
www.americanbankingnews.com - April 4 at 11:10 PM
Miragen Therapeutics, Inc. (MGEN) to Post Q1 2018 Earnings of ($0.27) Per Share, B. Riley ForecastsMiragen Therapeutics, Inc. (MGEN) to Post Q1 2018 Earnings of ($0.27) Per Share, B. Riley Forecasts
www.americanbankingnews.com - March 30 at 6:52 AM
Head to Head Review: Miragen Therapeutics (MGEN) vs. Its PeersHead to Head Review: Miragen Therapeutics (MGEN) vs. Its Peers
www.americanbankingnews.com - March 29 at 5:24 PM
Miragen Therapeutics (MGEN) Research Coverage Started at Jefferies GroupMiragen Therapeutics (MGEN) Research Coverage Started at Jefferies Group
www.americanbankingnews.com - March 29 at 9:18 AM
Wedbush Reaffirms "Outperform" Rating for Miragen Therapeutics (MGEN)Wedbush Reaffirms "Outperform" Rating for Miragen Therapeutics (MGEN)
www.americanbankingnews.com - March 28 at 8:06 AM
miRagen Therapeutics (MGEN) Reports Initiation of Phase 1 Clinical Trial of MRG-110miRagen Therapeutics (MGEN) Reports Initiation of Phase 1 Clinical Trial of MRG-110
www.streetinsider.com - March 28 at 5:33 AM
miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110
finance.yahoo.com - March 27 at 3:15 PM
Wedbush Analysts Lift Earnings Estimates for Miragen Therapeutics, Inc. (MGEN)Wedbush Analysts Lift Earnings Estimates for Miragen Therapeutics, Inc. (MGEN)
www.americanbankingnews.com - March 23 at 7:46 AM
Miragen Therapeutics (MGEN) Receives New Coverage from Analysts at Deutsche BankMiragen Therapeutics (MGEN) Receives New Coverage from Analysts at Deutsche Bank
www.americanbankingnews.com - March 22 at 8:42 PM
Miragen Therapeutics, Inc. Expected to Earn FY2022 Earnings of ($0.96) Per Share (MGEN)Miragen Therapeutics, Inc. Expected to Earn FY2022 Earnings of ($0.96) Per Share (MGEN)
www.americanbankingnews.com - March 22 at 5:54 PM
Miragen Therapeutics, Inc. (MGEN) Given Average Rating of "Buy" by BrokeragesMiragen Therapeutics, Inc. (MGEN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 21 at 10:45 AM
Miragen: Our Take On This RNA Play - Miragen Therapeutics, Inc ... - Seeking AlphaMiragen: Our Take On This RNA Play - Miragen Therapeutics, Inc ... - Seeking Alpha
seekingalpha.com - March 19 at 3:04 PM
Q1 2018 Earnings Forecast for Miragen Therapeutics, Inc. Issued By B. Riley (MGEN)Q1 2018 Earnings Forecast for Miragen Therapeutics, Inc. Issued By B. Riley (MGEN)
www.americanbankingnews.com - March 19 at 1:53 AM
Miragen Therapeutics, Inc. (MGEN) Forecasted to Earn Q1 2019 Earnings of ($0.29) Per ShareMiragen Therapeutics, Inc. (MGEN) Forecasted to Earn Q1 2019 Earnings of ($0.29) Per Share
www.americanbankingnews.com - March 16 at 12:56 PM
Miragen Therapeutics (MGEN) Posts Quarterly  Earnings Results, Beats Estimates By $0.04 EPSMiragen Therapeutics (MGEN) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - March 15 at 1:26 PM
miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - March 15 at 5:11 AM
miRagen Therapeutics (MGEN) CEO William Marshall on Q4 2017 Results - Earnings Call Transcript - Seeking AlphamiRagen Therapeutics' (MGEN) CEO William Marshall on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 15 at 5:11 AM
miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 15 at 5:11 AM
Miragen Therapeutics (MGEN) Research Coverage Started at Evercore ISIMiragen Therapeutics (MGEN) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - March 9 at 3:23 PM
UPDATE: Evercore ISI Starts miRagen Therapeutics (MGEN) at ... - StreetInsider.comUPDATE: Evercore ISI Starts miRagen Therapeutics (MGEN) at ... - StreetInsider.com
www.streetinsider.com - March 9 at 3:15 PM
miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - GlobeNewswire (press release)miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 3:07 PM
miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 14, 2018miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 14, 2018
finance.yahoo.com - March 7 at 3:07 PM
miRagen Therapeutics to Participate in Upcoming Investor ... - GlobeNewswire (press release)miRagen Therapeutics to Participate in Upcoming Investor ... - GlobeNewswire (press release)
globenewswire.com - March 5 at 3:20 PM
miRagen Therapeutics to Participate in Upcoming Investor ConferencesmiRagen Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - March 5 at 3:20 PM
$1.22 Million in Sales Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter$1.22 Million in Sales Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter
www.americanbankingnews.com - March 3 at 3:02 AM
 Brokerages Expect Miragen Therapeutics, Inc. (MGEN) to Announce -$0.32 EPS Brokerages Expect Miragen Therapeutics, Inc. (MGEN) to Announce -$0.32 EPS
www.americanbankingnews.com - March 1 at 7:07 PM
Miragen Therapeutics, Inc. (MGEN) Receives Consensus Recommendation of "Buy" from AnalystsMiragen Therapeutics, Inc. (MGEN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 24 at 9:54 AM
Miragen Therapeutics, Inc. (MGEN) Insider Adam Scott Levy Buys 9,090 SharesMiragen Therapeutics, Inc. (MGEN) Insider Adam Scott Levy Buys 9,090 Shares
www.americanbankingnews.com - February 13 at 6:46 PM
Bruce Booth Purchases 545,454 Shares of Miragen Therapeutics, Inc. (MGEN) StockBruce Booth Purchases 545,454 Shares of Miragen Therapeutics, Inc. (MGEN) Stock
www.americanbankingnews.com - February 13 at 6:10 PM
 Analysts Expect Miragen Therapeutics, Inc. (MGEN) Will Post Earnings of -$0.32 Per Share Analysts Expect Miragen Therapeutics, Inc. (MGEN) Will Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - February 13 at 3:14 AM
miRagen Therapeutics, Inc. Prices Public Offering of Common StockmiRagen Therapeutics, Inc. Prices Public Offering of Common Stock
finance.yahoo.com - February 9 at 5:01 AM
miRagen Therapeutics (MGEN) Announces Proposed 7M Share Common OfferingmiRagen Therapeutics (MGEN) Announces Proposed 7M Share Common Offering
www.streetinsider.com - February 5 at 3:08 PM

SEC Filings

Miragen Therapeutics (NASDAQ:MGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Miragen Therapeutics (NASDAQ:MGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Miragen Therapeutics (NASDAQ MGEN) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.